Search

Fate Therapeutics Inc

Закрыт

СекторЗдравоохранение

2.48 -3.88

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

2.45

Макс.

2.63

Ключевые показатели

By Trading Economics

Доход

1.2M

-31M

Продажи

-70K

1.3M

Прибыль на акцию

-0.26

Рентабельность продаж

-2,402.848

Сотрудники

161

EBITDA

14M

-28M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+101.54% upside

Дивиденды

By Acuity

Следующий отчет о доходах

10 авг. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

38M

291M

Предыдущая цена открытия

6.36

Предыдущая цена закрытия

2.48

Новостные настроения

By Acuity

14%

86%

24 / 340 Рейтинг в Healthcare

Fate Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

5 авг. 2026 г., 19:56 UTC

Fate Therapeutics shares are higher amid positive market sentiment and falling oil prices, despite some volatility during Wednesday's trading session.

4 авг. 2026 г., 20:07 UTC

News
Correlated Moves

Fate Therapeutics is gaining as it announces employee inducement awards, including stock options at $2.45 per share. Shares rebounded after an earlier pullback.

3 авг. 2026 г., 23:01 UTC

News

Fate Therapeutics Inc. shares are lower in after-market trading, despite stronger growth in the manufacturing sector and recent employee inducement awards.

29 июл. 2026 г., 19:19 UTC

Fate Therapeutics is trading higher amid positive market momentum ahead of the Federal Reserve's monetary policy announcement, despite lingering inflation concerns.

28 июл. 2026 г., 16:06 UTC

Fate Therapeutics shares are lower amid broader market weakness and investor caution ahead of key earnings reports and the Federal Reserve's interest rate decision.

27 июл. 2026 г., 21:02 UTC

Fate Therapeutics shares are higher in after-market hours, despite no specific news. Broader market sentiment is improving with rising European equity indices.

24 июл. 2026 г., 19:07 UTC

Correlated Moves

Fate Therapeutics shares are lower, pressured by a notable decline in first-quarter results and broader market sentiment. They remain below the 20-day moving average.

23 июл. 2026 г., 21:11 UTC

Fate Therapeutics Inc. shares are higher in after-market hours, reflecting broader market gains. No specific company news has been identified to explain this increase.

22 июл. 2026 г., 23:46 UTC

Fate Therapeutics Inc shares are higher in after-market trading, reflecting a modest gain since Wednesday's close, despite no specific news identified.

20 июл. 2026 г., 18:26 UTC

Fate Therapeutics Inc. shares are effectively unchanged as trading remains flat. The stock has seen strong performance over the past month, nearing its recent highs.

Сравнение c конкурентами

Изменение цены

Fate Therapeutics Inc Прогноз

Целевая цена

By TipRanks

101.54% рост

Прогноз на 12 месяцев

Средняя 5.24 USD  101.54%

Максимум 8 USD

Минимум 2.2 USD

Основано на мнении 9 аналитиков Wall Street, спрогнозировавших целевые цены для Fate Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

9 ratings

5

Покупка

4

Удержание

0

Продажа

Настроения

By Acuity

24 / 340Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
help-icon Live chat